NEGR1 and neoplasm: In designing a therapeutic strategy to enhance an IgLON family TSG activity in tumor cells, two options have been considered: (a) whole-protein replacement therapy for OPCML [21,22,23] or (b) a peptide fragment derived from the first Ig domain for NEGR1 [24,25].